- Home
- PMO vs CATX Comparison
PMO vs CATX Comparison
Compare PMO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- CATX
- Stock Information
- Founded
- PMO 1993
- CATX 1983
- Country
- PMO United States
- CATX United States
- Employees
- PMO N/A
- CATX N/A
- Industry
- PMO Finance Companies
- CATX Medical/Dental Instruments
- Sector
- PMO Finance
- CATX Health Care
- Exchange
- PMO Nasdaq
- CATX Nasdaq
- Market Cap
- PMO 287.4M
- CATX 239.0M
- IPO Year
- PMO N/A
- CATX N/A
- Fundamental
- Price
- PMO $9.90
- CATX $3.60
- Analyst Decision
- PMO
- CATX Strong Buy
- Analyst Count
- PMO 0
- CATX 11
- Target Price
- PMO N/A
- CATX $12.90
- AVG Volume (30 Days)
- PMO 99.0K
- CATX 712.3K
- Earning Date
- PMO 01-01-0001
- CATX 08-13-2025
- Dividend Yield
- PMO 4.10%
- CATX N/A
- EPS Growth
- PMO N/A
- CATX N/A
- EPS
- PMO 0.42
- CATX N/A
- Revenue
- PMO N/A
- CATX $1,235,000.00
- Revenue This Year
- PMO N/A
- CATX N/A
- Revenue Next Year
- PMO N/A
- CATX $11.99
- P/E Ratio
- PMO $24.38
- CATX N/A
- Revenue Growth
- PMO N/A
- CATX N/A
- 52 Week Low
- PMO $8.57
- CATX $1.60
- 52 Week High
- PMO $10.68
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- PMO 57.77
- CATX 44.08
- Support Level
- PMO $9.80
- CATX $3.66
- Resistance Level
- PMO $9.96
- CATX $4.08
- Average True Range (ATR)
- PMO 0.07
- CATX 0.26
- MACD
- PMO 0.02
- CATX -0.04
- Stochastic Oscillator
- PMO 75.00
- CATX 19.40
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.